Order Article Reprints

Agbarya A, Sarel I, Ziv-Baran T, Agranat S, Schwartz O, Shai A, Nordheimer S, Fenig S, Shechtman Y, Kozlener E, et al. Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic Drugs. Cancers. 2021; 13(16):4191. https://doi.org/10.3390/cancers13164191

Agbarya, Abed, Ina Sarel, Tomer Ziv-Baran, Sivan Agranat, Orna Schwartz, Ayelet Shai, Sharon Nordheimer, Shlomit Fenig, Yelena Shechtman, Ella Kozlener, and et al. 2021. "Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic Drugs" Cancers 13, no. 16: 4191. https://doi.org/10.3390/cancers13164191

Agbarya, A., Sarel, I., Ziv-Baran, T., Agranat, S., Schwartz, O., Shai, A., Nordheimer, S., Fenig, S., Shechtman, Y., Kozlener, E., Taha, T., Nasrallah, H., Parikh, R., Elkoshi, N., Levy, C., Khoury, R., & Brenner, R. (2021). Efficacy of the mRNA-Based BNT162b2 COVID-19 Vaccine in Patients with Solid Malignancies Treated with Anti-Neoplastic Drugs. Cancers, 13(16), 4191. https://doi.org/10.3390/cancers13164191